Webinar takes in-depth look at the future of clinical research

By Jenni Spinner

- Last updated on GMT

(Sitthiphong/iStock via Getty Images Plus)
(Sitthiphong/iStock via Getty Images Plus)

Related tags Decentralized trials Remote monitoring Data management Wearables Bristol Myers Squibb COVID-19

OSP's free Digital Advances in Clinical Trial webinar (on December 9) will feature experts discussing recent advancements in the rapidly evolving field.

While cutting-edge clinical trial technologies like wearable monitoring devices, artificial intelligence, remote monitoring and others were around before COVID-19 pounced, many research professionals would likely now consider such tools indispensable in the face of the pandemic. Such emerging technology has expanded the possibility of data collection and analysis, but—with the virus bringing site activity to a crawl or total stop—it also has empowered trial teams to continue their work on developing much-needed treatments.

On December 9, any professionals interested in continuing their trials and introducing efficiencies are welcome to join Outsourcing-Pharma and some notable industry experts for Digital Advances in Clinical Trials: Clinical Development​. This free webinar gives us a chance to gather (in the virtual realm) to hear how various digital innovations are enabling sites and sponsors to not just keep their work going, but to take it to the next level.

The Outsourcing-Pharma team is thrilled to be hosting such a well-respected panel of trial experts to this online event:

Julia Moore Vogel, director of Scripps Research

Dr. Vogel will discuss the use of wearable devices in health research, as well as the All of Us Research Program. Her presentation will outline recent publications using 15m Fitbit users’ data to learn about individuals’ health and an algorithm that utilizes data to distinguish between those who do and don’t have COVID-19.

Joe Dustin, head of clinical innovation, Bristol Myers Squibb

Dustin, a technology expert turned pharmaceutical executive, will dive into how business priorities go from pilots into widespread adoption and change management as the industry heads into 2021.  Topics include decentralized trial technology and what’s needed to help it scale; digital biomarker; improved interoperability between sites, sponsors and CROs; and more.

Matthew Mullarkey, director of the Doctor of Business Administration Program for the University of South Florida’s Muma College of Business; and Asa Oxner, vice chair of the Department of Internal Medicine and director of COVID Testing and Follow Up Clinic at the University of South Florida

Mullarkey will present, and Oxner will join the discussion, regarding an innovative pilot study that collected de-identified vital sign and physiologic measurements from COVID-19 patients using wearables. Study objectives included determining ways such information could be harnessed to identify patients at risk of developing serious COVID-19 symptoms.

During the presentations, attendees are welcome to submit questions via the webinar interface. After our panel finishes their talks, our expert presenters will offer their thoughts about as many of the questions as time allows.

This enlightening event would not be possible without the generous support of our sponsors:

  • Advarra
  • Ajinomoto Biopharma Services
  • Elligo Health Research
  • Oracle Health Sciences

Sign up today for Digital Advances in Clinical Trials: Clinical Development​ and join your industry colleagues in a lively discussion about the future direction of clinical research. Please feel free to share this article with any colleagues you feel would benefit from the content of this online event.

Related events

View more

Innovations in Drug Delivery - Part II


In this editorial webinar, we bring together leading experts to discuss what major trends are occurring across the industry in the development of new methods of drug delivery, as well as improvements to existing ones. We aim to inform the listeners of the major advantages that can be gained by paying attention to the particular dosage forms of active pharmaceutical ingredients (APIs), whether to improve bioavailability or to allow for more convenient use by the patient.


Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more